semaglutide california ban update just got FDA-approved for kidney disease. This changes everything., January 2025. The FDA approved semaglutide (Ozempic/Wegovy) for a new indication: reducing kidney disease progression in States cracking down on compounding

[45] Healthcare providers should exercise caution when prescribing concurrent CNS depressants and may need to adjust dosages or implement enhanced monitoring strategies

What You Can Do: Track Your Progress: Instead of focusing solely on the number on the scale, celebrate other victorieslike improved energy levels, better sleep, or smaller clothing sizes

Current pricing, available medication formats, and full program terms should be confirmed directly with BreezeMeds before any enrollment or financial commitment

The lateral parabrachial nucleus may be a critical site of action as pharmacological activation of GLP-Rs in the lateral parabrachial nucleus (LPBN) inhibits feeding whereas antagonism of LPBN GLP-1Rs induces hyperphagia (Alhadeff et al., 2014)

That does not mean the medications failed

Three factors tend to matter most: Follow-up consistency Medication with no follow-up may be considered to be guesswork